Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Rank in Stocks #93
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and... Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Share Price
$137.21
Market Cap
$170.34B
Change (1 day)
-2.76%
Change (1 year)
28.14%
Country
US
Trade Gilead Sciences, Inc. (GILD)

Category

P/B ratio for Gilead Sciences, Inc. (GILD)
P/B ratio as of March 2026 TTM: 7.96
According to Gilead Sciences, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 7.96. At the end of 2024 the company had a P/B ratio of 5.96.
P/B ratio history for Gilead Sciences, Inc. from 2000 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 7.96 -100.00%
2025 0.00 -100.00%
2024 5.96 34.58%
2023 4.43 -12.71%
2022 5.07 17.19%
2021 4.33 7.59%
2020 4.02 9.82%
2019 3.66 -3.49%
2018 3.80 -17.12%
2017 4.58 -9.78%
2016 5.08 -36.48%
2015 7.99 -14.05%
2014 9.30 -7.89%
2013 10.10 68.83%
2012 5.98 27.09%
2011 4.71 -11.06%
2010 5.29 -13.96%
2009 6.15 -44.20%
2008 11.02 -10.79%
2007 12.35 -24.75%
2006 16.42 108.13%
2005 7.89 -2.41%
2004 8.08 -30.89%
2003 11.69 0.49%
2002 11.64 -15.83%
2001 13.83 28.66%
2000 10.75 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
33.3372 318.72%
US
6.0657 -23.81%
GB
7.1931 -9.65%
US
-119.6075 -1,602.29%
US
6.3334 -20.45%
CH